Novartis Wants Rival's Atty Booted From MS Drug Patent Suit
By Rose Krebs ( April 25, 2022, 4:48 PM EDT) -- Novartis Pharmaceutical Corp. continued to argue that a lawyer representing Shilpa Pharma Inc. must be disqualified because his testimony as a witness will likely be "central" to a patent dispute in Delaware federal court over a multiple sclerosis drug....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.